GE Healthcare, a unit of General Electric Company (NYSE: GE) landed FDA 510(k) clearance for its SenoBright contrast enhanced spectral mammography for breast cancer diagnosis.
Launched in 2010, the SenoBright system is already used in France, Spain, Italy, Belgium, Germany, Austria and Japan.
"Since 1965, GE Healthcare has made significant progress in providing solutions for breast cancer detection and diagnosis that really bring a change to people’s lives," GE Healthcare VP Anne LeGrand said in prepared remarks.
The SenoBright system is part of GE’s renewed focus on breast cancer as part of a $1 billion investment into oncology research over the next five years.
The first part of its initiative was GE Healthcare’s recently unveiled SenoCase ultra-portable mammography device, which aims to combine mobility and affordability to provide breast cancer screening in underserved areas, especially in emerging markets.
- RenalGuard gets FDA nod for pivotal U.S. study
PLC System Inc. received FDA approval to commence U.S. trials for its RenalGuard therapy and RenalGuard system for contrast-induced nephropathy.
- Freedom Meditech submits its first 510(k) application
Freedom Meditech submitted its first round of paperwork to the FDA for the company’s ClearPath DS-120 lens fluorescence biomicroscope.
- ISTO lands CE Mark approval
Orthobiologics company ISTO Technologies landed CE Mark approval for its InQu bone graft substitute and extender.
- Cloud-based software maker announces FDA clearance
Candelis Inc. received 510(k) clearance from the federal watchdog agency for its Astra cloud-hosted medical software suite.
- Carticept lands FDA clearance for its Navigator delivery system
Alpharetta, Ga.-based Carticept Medical landed FDA approval for its Navigator automated injection system with integrated ultrasound guidance.